Last reviewed · How we verify
1. Optive
At a glance
| Generic name | 1. Optive |
|---|---|
| Sponsor | Innovative Medical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests (PHASE4)
- An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
- An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
- The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability (NA)
- Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® (PHASE1)
- Artificial Tears, Tear Lipids and Tear Film Dynamics (PHASE4)
- Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease (PHASE4)
- Tear Lipid Layer Thickness With Emollient Eye Drops (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1. Optive CI brief — competitive landscape report
- 1. Optive updates RSS · CI watch RSS
- Innovative Medical portfolio CI